Sequana Medical NV (FRA:2SE) Interest Expense: €-10.89 Mil (TTM As of Jun. 2025)


FRA:2SE Sequana Medical NV FRA:2SE
31 GF Score
Price €0.51
GF Value €0.19
! 12 Warning Signs
View Full Analysis

What is Sequana Medical NV Interest Expense?

Sequana Medical NV FRA:2SE 31 Interest Expense is €-10.89 Mil as of Jun. 2025. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sequana Medical NV's interest expense for the six months ended in Jun. 2025 was € -12.76 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2025 was €-10.89 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sequana Medical NV's Operating Income for the six months ended in Jun. 2025 was € -8.58 Mil. Sequana Medical NV's Interest Expense for the six months ended in Jun. 2025 was € -12.76 Mil. Sequana Medical NV did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sequana Medical NV  (FRA:2SE) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sequana Medical NV's Interest Expense for the six months ended in Jun. 2025 was €-12.76 Mil. Its Operating Income for the six months ended in Jun. 2025 was €-8.58 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2025 was €0.73 Mil.

Sequana Medical NV's Interest Coverage for the quarter that ended in Jun. 2025 is calculated as

Sequana Medical NV did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sequana Medical NV Interest Expense Historical Data

* Premium members only.

The historical data trend for Sequana Medical NV's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sequana Medical NV Interest Expense Chart

Sequana Medical NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.08 -0.56 -0.88 -1.99 -2.64

Sequana Medical NV Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.11 0.12 -4.51 1.88 -12.76
FRA:2SE
31GF Score
Sequana Medical NV FRA:2SE
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sequana Medical NV Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-10.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-10.89 Mil mean?
Sequana Medical NV (FRA:2SE) has a Interest Expense of €-10.89 Mil as of Jun. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sequana Medical NV and its competitors.
Is Sequana Medical NV's Interest Expense too high?
Sequana Medical NV's current Interest Expense is €-10.89 Mil. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Interest Expense compare to ABT and SYK?
Sequana Medical NV's Interest Expense of €-10.89 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sequana Medical NV and its competitors. Sequana Medical NV's current Interest Expense is €-10.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current Interest Expense of €-10.89 Mil. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current Interest Expense is €-10.89 Mil. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current Interest Expense is €-10.89 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:2SE:

  • Interest Expense: €-10.89 Mil
  • GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
  • GF Score™: 31/100 with 12 warning signs

No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sequana Medical NV Business Description

Other Exchanges 2SE:GermanySEQUA:Belgium
Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score

Get the complete analysis for FRA:2SE

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.19
GF Value